CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Aug 1, 2020--

Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (“Takeda”), today presented three abstracts at the 72 nd National Hemophilia Foundation’s Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.

Copyright Business Wire 2020.